These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1447 related articles for article (PubMed ID: 21343559)

  • 1. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
    Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
    Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 4. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
    Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D
    Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.